Compare AVXL & ECOR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | AVXL | ECOR |
|---|---|---|
| Founded | 2004 | 2005 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Electromedical & Electrotherapeutic Apparatus |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 115.9M | 100.3M |
| IPO Year | 2013 | 2018 |
| Metric | AVXL | ECOR |
|---|---|---|
| Price | $1.26 | $8.40 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $19.17 |
| AVG Volume (30 Days) | ★ 1.2M | 72.7K |
| Earning Date | 11-24-2026 | 11-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $32,032,000.00 |
| Revenue This Year | N/A | $30.85 |
| Revenue Next Year | N/A | $29.71 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ 27.20 |
| 52 Week Low | $1.13 | $4.41 |
| 52 Week High | $7.60 | $12.70 |
| Indicator | AVXL | ECOR |
|---|---|---|
| Relative Strength Index (RSI) | 27.79 | 37.69 |
| Support Level | $1.14 | $6.94 |
| Resistance Level | $1.60 | $8.26 |
| Average True Range (ATR) | 0.10 | 0.70 |
| MACD | 0.02 | 0.00 |
| Stochastic Oscillator | 14.89 | 26.99 |
Anavex Life Sciences Corp is a clinical stage biopharmaceutical company engaged in the development of differentiated therapeutics by applying precision medicine to central nervous system(CNS) diseases with high unmet need. It analyzes genomic data from clinical trials to identify biomarkers, which are used in the analysis of its clinical trials for the treatment of neurodegenerative and neurodevelopmental diseases. The company focuses on developing treatments for Alzheimer's disease, Parkinson's disease, schizophrenia, neurodevelopmental, neurodegenerative, and rare diseases, including Rett syndrome, and other central nervous system (CNS) disorders. Its pipeline includes ANAVEX 2-73 and ANAVEX 3-71 and several other compounds in different stages of clinical and pre-clinical development.
electroCore Inc is a bioelectronic technology company whose mission is to improve health and quality of life through non-invasive bioelectronic technologies. Its two commercial products are gammaCore non-invasive vagus nerve stimulation, or nVNS, and Quell Fibromyalgia, or Quell. It also sells Truvaga and TAC-STIM products, which are handheld, personal-use consumer products developed to promote general wellness and human performance. It operates in one segment: Bioelectronic Innovations. Geographically, it operates in the United States, the United Kingdom, Japan, and Other.